Explore the words cloud of the TherVacB project. It provides you a very rough idea of what is the project "TherVacB" about.
The following table provides information about the project.
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
|Coordinator Country||Germany [DE]|
|Total cost||10˙425˙686 €|
|EC max contribution||10˙425˙686 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2020-01-01 to 2024-12-31|
Take a look of project's partnership.
|1||HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH||DE (NEUHERBERG)||coordinator||4˙049˙761.00|
|2||KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN||DE (MUENCHEN)||participant||1˙394˙787.00|
|3||CTC NORTH GMBH & CO KG||DE (HAMBURG)||participant||1˙113˙125.00|
|4||AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA||IT (PARMA)||participant||714˙893.00|
|5||LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN||DE (MUENCHEN)||participant||675˙380.00|
|6||UNIVERSITY COLLEGE LONDON||UK (LONDON)||participant||536˙023.00|
|7||NATIONAL INSTITUTE FOR MEDICAL RESEARCH||TZ (DAR ES SALAAM)||participant||489˙287.00|
|9||UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF||DE (HAMBURG)||participant||209˙350.00|
|10||TECHNISCHE UNIVERSITAET MUENCHEN||DE (MUENCHEN)||participant||191˙556.00|
|11||FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA||ES (BARCELONA)||participant||153˙750.00|
|12||HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH||DE (BRAUNSCHWEIG)||participant||146˙500.00|
|13||UNIVERSITAET LEIPZIG||DE (LEIPZIG)||participant||142˙900.00|
|14||MEDIZINISCHE HOCHSCHULE HANNOVER||DE (HANNOVER)||participant||131˙125.00|
|15||BARTS AND THE LONDON NHS TRUST||UK (LONDON)||participant||104˙500.00|
|16||ROYAL FREE LONDON NHS FOUNDATION TRUST||UK (LONDON)||participant||100˙000.00|
Experts in virology, immunology and clinical hepatitis B patient care with an excellent research and translational track record in hepatitis B virus (HBV)-host interaction form the interdisciplinary TherVacB consortium. They jointly tackle the major challenges in HBV therapy – the virus’s resistance to cure. TherVacB aims at breaking immune tolerance in chronic HBV infection and achieving HBV cure. Occurrence of neutralizing antibodies and HBV-specific T cell responses characterize spontaneous resolution of HBV infection that are lacking in chronic infection. We will use our IP-protected heterologous prime-boost therapeutic vaccination scheme with proven efficacy in preclinical models of hepatitis B to target and activate B and T cell responses. Two protein prime injections with clinically approved, adjuvanted particulate HBV S and core protein antigens shall induce neutralizing antibodies and prime T cells that are boosted with an MVA vector expressing HBV core, S, L and polymerase antigens covering >95% of HBV found worldwide. Having secured significant funding and partnerships to obtain GMP-produced vaccine components and to prepare a first-in-human application, TherVacB aims at a clinical proof-of-concept of the therapeutic hepatitis B vaccine in patients with chronic hepatitis B. The consortium will establish a patient registry and perform a multi-center phase Ib/IIa clinical trial that aims at proving safety of the therapeutic vaccine and inducing immune control of chronic HBV infection. One study arm will be realized in Tanzania to build up local capacity, because Africa carries a large burden of HBV infection but lacks diagnostic and therapeutic options. An innovative immune monitoring will quantify HBV-specific immunity and define novel biomarkers to predict treatment response. Finally an ethical and an empirical study will evaluate the recruitment of patients by social media which is very effective for infectious diseases that tend to stigmatize patients
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERVACB" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "THERVACB" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More